Overview

Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer

Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether positron emission tomography / computed tomography (PET/CT) using fluorine-18 fluorocholine as an imaging agent can characterize regional responses to anti-androgen therapies in a manner that in the future aid in the customized planning of treatments for patients with androgen-insensitive prostate cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Queen's Medical Centre
Collaborator:
National Institutes of Health (NIH)
Treatments:
Androgen Antagonists
Androgens
Fluorides